Improved functionality includes information sharing, interactivity and new media space
PARIS, Sept. 22 /PRNewswire/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, has announced the launch of its new corporate website. Visitors to this new website are ensured an enhanced usability and information sharing, including more streamlined access to technology and product-related information.
The new Cellectis website focuses on three central themes:
- Research and Technologies
- Business Development
- Investor relations.
In addition to these key areas, the website offers new features and fresh content including:
- Several specific RSS feeds which enables users to monitor the Company's business in real time, choosing only the subjects they are interested in
- Social media links (Facebook and Twitter)
- Downloadable documents that explains Cellectis' technology.
Founded in 1999 by Andre Choulika, PhD and David Sourdive, PhD, Cellectis today has a workforce of over 120 people and 4 subsidiaries, including one located in the U.S. Due to a steady increase in business over the past several months, Cellectis decided to offer its web visitors a showcase that presents the Company' businesses, products and achievements in the most comprehensive manner possible.
Other highlights include the following:
- A glossary, containing all definitions required to keep up-to-date with Cellectis' activities
- A graphic library available to qualified journalists, which includes photographs of Cellectis' products and facilities, classified by theme. Journalists need only to register to access and download the files.
The new website can be accessed at: www.cellectis.com.
About Cellectis
Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools – meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.
To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending. Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over euro 70 million in funding since inception.
More information at www.cellectis.com
Follow our news on Twitter: twitter.com/cellectis.
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
SOURCE Cellectis